--- title: FidoCure blog (6) description: Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates. (6) --- [![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/) - [Veterinarians](https://fidocure.com/for-veterinarians/) - [Portal Login](https://dvm.fidocure.com/) - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet) - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars) - [Pet Parents](https://fidocure.com/pet-parents/) - [About Us](https://fidocure.com/about-us/) - [How it works](https://fidocure.com/how-it-works/) - [Find a Clinic](https://fidocure.com/find-a-clinic/) - [Contact Us](https://fidocure.com/contact-us/) # FidoCure Veterinary Team Blog ### Read the latest in veterinary oncology research and FidoCure scientific and clinical updates from our team of experts and advisors Select Category Case Studies Press Vet Webinars This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. ![](https://blog.fidocure.com/hubfs/pixelle.jpg) ### [Adrenocortical Carcinoma Case Study: Pixelle](https://blog.fidocure.com/fidocure-blog/adrenocortical-carcinoma-case-study-pixelle) ##### **History and Initial Treatment** Pixelle, a 13 year old Shih Tzu, started her long cancer journey in June of 2020 when she was diagnosed with a left-sided adrenal mass after undergoing a thorough workup for vomiting, polyuria/polydipsia, and intermittent urinary incontinence. A pheochromocytoma was ruled out as a low-dose dexamethasone suppression test was consistent with Cushing’s Disease (cortisol secreting tumor).  [Read More](https://blog.fidocure.com/fidocure-blog/adrenocortical-carcinoma-case-study-pixelle) ![](https://blog.fidocure.com/hubfs/Identification%20of%20genomic%20alterations%20with%20clinical%20impact%20in%20canine%20splenic%20hemangiosarcoma%20(600%20x%20400%20px)-1.png) ### [Precision Medicine in Veterinary Science: Veterinary Clinics of North America](https://blog.fidocure.com/fidocure-blog/elsevier) **Revolutionizing Veterinary Oncology: Precision Medicine Paves the Way for Personalized Cancer Treatment in Dogs** [Read More](https://blog.fidocure.com/fidocure-blog/elsevier) ![](https://blog.fidocure.com/hubfs/2023%20(1).png) ### [A Year of Breakthroughs: A look back at 2023](https://blog.fidocure.com/fidocure-blog/a-year-of-breakthroughs-a-look-back-at-2023) We would like to express our heartfelt gratitude to our veterinary community as we come to the close of the year. Together, we have made a tremendous impact by enabling precision medicine to nearly **5,000 pet dogs battling cancer**.  [Read More](https://blog.fidocure.com/fidocure-blog/a-year-of-breakthroughs-a-look-back-at-2023) ![](https://blog.fidocure.com/hubfs/iStock-1258105499.jpg) ### [Innovative Bioinformatics Pipeline Reduces Costs and Expands Access to Precision Therapeutics for Canine Oncology](https://blog.fidocure.com/fidocure-blog/innovative-bioinformatics-pipeline-reduces-costs-and-expands-access-to-precision-therapeutics-for-canine-oncology) Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript ["Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics,](https://www.nature.com/articles/s41598-023-37505-2?fbclid=IwAR0dZ8PUQB3BmX-8OeySAKt-1aMPmHqPeJId93WhmpeweMEKGq0XkBwRLw4)" recently published in[Scientific Reports](https://www.nature.com/articles/s41598-023-37505-2?fbclid=IwAR0dZ8PUQB3BmX-8OeySAKt-1aMPmHqPeJId93WhmpeweMEKGq0XkBwRLw4). [Read More](https://blog.fidocure.com/fidocure-blog/innovative-bioinformatics-pipeline-reduces-costs-and-expands-access-to-precision-therapeutics-for-canine-oncology) ![](https://blog.fidocure.com/hubfs/Identification%20of%20genomic%20alterations%20with%20clinical%20impact%20in%20canine%20splenic%20hemangiosarcoma%20(6).png) ### [Canine Cancer Osteosarcoma Research](https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research) In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition. [Read More](https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research) ![](https://blog.fidocure.com/hubfs/cells.jpg) ### [Mammary Carcinoma: Insights from BRCA1 mutations](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations) **Genetic Signatures in Canine Mammary Tumors: insights from *BRCA1* mutations** [Read More](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations) ![](https://blog.fidocure.com/hubfs/iStock-1128072732.jpg) ### [Veterinary Technician Week: Giveaway](https://blog.fidocure.com/fidocure-blog/vettechgiveaway) ##### **Thank you to all the veterinary technicians who have helped us enroll over 4500 dogs on the FidoCure platform. We are so thankful for your partnership in fighting cancer on both ends of the leash! ** Enter below for your chance to win: [Read More](https://blog.fidocure.com/fidocure-blog/vettechgiveaway) ![](https://blog.fidocure.com/hubfs/Maggie%20Donahue%20photo%20(1)-1.jpg) ### [Case Study: Malignant Oral Melanoma](https://blog.fidocure.com/fidocure-blog/malignant-oral-melanoma) ##### **History and Treatment Planning** Maggie, a friendly and rambunctious 12 year old, spayed female pug, was diagnosed with malignant oral melanoma in March 2022 by her primary care veterinarian. The mass was located on her upper left dental arcade. Her veterinarian surgically debulked approximately 80% of the mass. Unfortunately, Maggie experienced rapid local recurrence within a month of the surgery, involving the maxilla, and the adjacent mandibular lymph node. [Read More](https://blog.fidocure.com/fidocure-blog/malignant-oral-melanoma) ![](https://blog.fidocure.com/hubfs/Identification%20of%20genomic%20alterations%20with%20clinical%20impact%20in%20canine%20splenic%20hemangiosarcoma%20(2).png) ### [Precision Medicine Tools Offer Veterinarians New Hope for Understanding Hemangiosarcoma](https://blog.fidocure.com/fidocure-blog/vco) FOR IMMEDIATE RELEASE Precision Medicine Tools Offer Veterinarians New Hope for Understanding Deadly Dog Cancer [Read More](https://blog.fidocure.com/fidocure-blog/vco) ![](https://blog.fidocure.com/hubfs/iStock-500430393.jpg) ### [Undifferentiated Oral Malignancy Case Study](https://blog.fidocure.com/fidocure-blog/undifferentiated-oral-malignancy-case-study) ##### **History and Treatment Planning** A 12 year old, neutered male Golden Retriever, underwent a dental prophylaxis procedure performed by his primary care veterinarian in June of 2021. At that time, no suspicious lesions or growths were noted. In October 2021, his family discovered a marble-sized growth in his mouth along the gum line of his left maxilla. The mass was visible from the outside of his mouth, and seemed to cause him irritation. At the time, it was bloody (perhaps from self trauma/stick chewing). Antibiotics were prescribed, but the dog quickly developed worsening clinic signs (nasal discharge, swelling, lethargy).  [Read More](https://blog.fidocure.com/fidocure-blog/undifferentiated-oral-malignancy-case-study) [4](https://blog.fidocure.com/fidocure-blog/page/4) [5](https://blog.fidocure.com/fidocure-blog/page/5) [6](https://blog.fidocure.com/fidocure-blog/page/6) [7](https://blog.fidocure.com/fidocure-blog/page/7) [8](https://blog.fidocure.com/fidocure-blog/page/8) ![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg) - [How it Works](https://fidocure.com/how-it-works/) - [FAQ](https://fidocure.com/faq/) - [Contact Us](https://fidocurestg.wpengine.com/contact-us/) - [For Vets](https://fidocure.com/for-veterinarians/) - [About Us](https://fidocure.com/about-us/) - [Terms of Service](https://fidocure.com/terms-of-service/) - [Blog](https://blog.fidocure.com/fidocure-blog) - [Careers](https://fidocure.com/careers/) - [Privacy Policy](https://fidocure.com/privacy-policy/) - - - - **FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.  © Copyright 2018-2026 One Health Company, All rights reserved